Francis Medical Highlights Clinical Progress of Vanquish System at EAU Congress

According to a recent LinkedIn post from Francis Medical, the company is highlighting its participation at the European Association of Urology Congress (EAU26) and engagement with the urology community. The post references a dinner event and presentation featuring Dr. Arvin K. George, who discussed patient experience data from the VAPOR 2 Study.

The post suggests that VAPOR 2 is a novel, multi-center clinical trial evaluating the Vanquish Water Vapor Ablation System, a transurethral thermal water vapor technique intended to ablate prostate tissue. Data have reportedly been reported on the first 110 patients with 12‑month follow‑up, indicating growing clinical evidence around the technology.

As shared in the LinkedIn content, Vanquish is described as an FDA‑cleared, prescription‑only device, with additional safety information available on the company’s website. For investors, the emphasis on evidence‑based outcomes and multi‑center trial data may signal progress toward broader physician adoption and potential future reimbursement support.

The focus on engagement with leading urologists at EAU26 also points to a strategy centered on specialist education and clinical validation rather than consumer‑direct marketing. If positive VAPOR 2 results are sustained and expanded, Francis Medical could strengthen its competitive position in the minimally invasive treatment segment for prostate conditions and potentially enhance its long‑term revenue prospects.